Related Experiment Video

Updated: Jun 20, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas

Brian Hutzen1, Lauren Friedman, Matthew Sobo

  • 1Department of Pediatrics, Tohoku University, Sendai, Japan.

International Journal of Oncology
|September 3, 2009
PubMed

Insights

A new curcumin analogue, GO-Y030, shows potent anti-cancer effects by reducing cell viability and inhibiting STAT3 activation in breast and pancreatic cancer cells. This compound demonstrates improved efficacy over curcumin, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Curcumin exhibits anti-carcinogenic properties but suffers from poor bioavailability, limiting its therapeutic use.
  • Synthetic analogues are being developed to overcome curcumin's limitations.
  • Signal transducer and activator of transcription 3 (STAT3) is a key factor in cancer progression.

Purpose of the Study:

  • To evaluate the efficacy of the curcumin analogue GO-Y030 in human breast and pancreatic cancer cells.
  • To compare the effects of GO-Y030 and curcumin on cancer cell viability and apoptosis.
  • To investigate the impact of GO-Y030 on STAT3 activation.

Main Methods:

  • Testing GO-Y030 and curcumin on human breast (MDA-MB-231) and pancreatic cancer cell lines (PANC-1, HPAC, BXPC-3).
  • Assessing cell viability and apoptosis induction.
  • Analyzing STAT3 phosphorylation and transcriptional activity.

Main Results:

  • Both curcumin and GO-Y030 reduced cell viability and induced apoptosis.
  • GO-Y030 demonstrated significantly higher potency than curcumin.
  • GO-Y030 effectively inhibited STAT3 phosphorylation and transcriptional activity, while curcumin had minimal effect.

Conclusions:

  • GO-Y030 is a potent inhibitor of cancer cell viability and STAT3 activation.
  • GO-Y030 shows promise as a therapeutic agent for cancers with high STAT3 activation.
  • The synthetic analogue GO-Y030 offers an improved therapeutic strategy compared to curcumin.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...